Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Clotrimazole is a broad-spectrum antifungal medication in the imidazole class, primarily used to treat various fungal infections such as tinea corporis (ringworm), tinea cruris (jock itch), tinea pedis (athlete's foot), cutaneous candidiasis, oral thrush, vaginal yeast infections, diaper rash, and tinea versicolor. Its mechanism of action involves inhibiting the enzyme lanosterol 14-alpha demethylase in fungi, which impairs ergosterol synthesis—a critical component of the fungal cell membrane—leading to increased membrane permeability and inhibition of fungal growth. At higher concentrations, it may be fungicidal. Clotrimazole also exhibits additional pharmacological effects by inhibiting sarcoplasmic reticulum Ca2+-ATPase and blocking certain calcium-dependent channels[1][2][3][5].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on clotrimazole.